BioNumerik Launches Phase III Trial To Confirm Surprising Tavocept Survival Benefit In NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Meta-analysis of secondary endpoint data from earlier chemoprotection trials revealed as much as 6.7 months survival benefit compared to one or two months with current regimens.